Home/ Stocks/ BDTX

Black Diamond Therapeutics, Inc. Common Stock

BDTX XNAS

$2.99 +0.30 (+11.03%) ▲ 15-min delayed

Open

$2.72

High

$3.15

Low

$2.70

Volume

1.66M

Market Cap

$171.33M

About Black Diamond Therapeutics, Inc. Common Stock

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 21 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$70.00M	$22.37M	$0.39
FY 2025	$70.00M	$22.37M	$0.39
Q3 2025	$0	$-8,498,000	$-0.15
Q2 2025	$0	$-10,561,000	$-0.19

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for BDTX yet. Check out our latest market news or earnings calendar.

Get BDTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Black Diamond Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.